dr. (Ken) WK Redekop

dr. (Ken) WK Redekop
Associate professor Erasmus School of Health Policy & Management Health Technology Assessment (HTA)
Location
Burg. Oudlaan 50, Rotterdam
Room
J8-29
Email
redekop@eshpm.eur.nl

More information

Back to overview

Profile

Ken Redekop, Ph.D. is an associate professor at the Institute for Medical Technology Assessment, Erasmus Universiteit Rotterdam, The Netherlands. He is a clinical epidemiologist with more than 20 years of experience in observational research, clinical trial analysis, and medical technology assessment and an author of over 100 papers in the medical literature. Current studies include early-stage cost-effectiveness analyses of medical devices and tests, RCT-based economic evaluations, economic evaluations in the Diagnostics Assessment programme of the National Institute for Health and Clinical Excellence (NICE, UK) and outcomes research studies to determine the effectiveness and cost-effectiveness of expensive medicines in daily practice. Most studies relate to diabetes, cardiovascular disease, and cancer, and most involve modelling and evidence synthesis.

  • M Westwood, H Raatz, K Misso, LT (Laura) Burgers, Ken Redekop, SK (Stefan) Lhachimi, N Armstrong & J Kleijnen (2013) - Systematic review of the accuracy of dual-source cardiac CT for detection of arterial stenosis in difficult to image patient groups - Radiology, 267 (2), 387-395 - doi: 10.1148/radiol.13121136/-/DC1
  • CO Agyemang, Anton Kunst, R Bhopal, P Zaninotto, N Unwin, J Nazroo, M Nicolaou, Ken Redekop & VM Adao (2011) - Hypertensie in Nederlandse en Engelse etnische minderheidsgroepen - Nederlands Tijdschrift voor Geneeskunde, A3318 (155), 1-9
  • Martin Ineveld, Peter Dohmen & Ken Redekop (2006) - De startende marktwerking in de gezondheidszorg - Economisch-Statistische Berichten, 91 (4494), 470-473
  • J Raad & Ken Redekop (2004) - A comparison between two systems for pre-employment medical assessment in the Royal Netherlands Army by a randomized, controlled study - Military Medicine, 169, 437-443
  • Ken Redekop & Marc Koopmanschap (2004) - Economische aspecten van polyfarmacie bij diabetes - CBO, 8-22

  • KA Phillips, K Payne & Ken Redekop (2016) - Personalized Medicine: Economic Evaluation and Evidence - World Scientific
  • RMF van Schie, TI Verhoef, AH Maitland-van der Zee, A de Boer, FJM van der Meer, Ken Redekop & R Thariani (2012) - Future of Pharmacogenetics in Cardiovascular Diseases - doi: 10.5772/2218 - InTech
  • Siok Swan Tan, L Serden, A Geissler, Martin Ineveld, Ken Redekop, M Heurgren & Leona Roijen (2011) - DRGs and cost accounting: Which is driving which? - Open University Press
  • Siok Swan Tan, Martin Ineveld, Ken Redekop & Leona Roijen (2011) - The Netherlands: The Diagnose Behandeling Combinaties - Open University Press

  • Ken Redekop (2017) - Personalised medicine to improve cardiovascular health - The Hippocrates Press

  • HE (Bertien) Hart, Ken Redekop, HJG Bilo, Jan Busschbach & AF (Anton) Casparie (2001) - Quality of life over time in a cohort of patients with type 1 diabetes mellitus measured with the Euroqol and the SF-36

  • Carin Uyl - de Groot, Ken Redekop, Amir Ansaripour, K. Zendehdel, N. Tadayon & F. Sadeghi (2016) - Use of data-mining to perform a real world cost analysis of HER2-positive breast cancer in Iran

Afstudeerproject

Level
bachelor 3
Year
2021
Year Level
bachelor 3
Course Code
GW310

Master Thesis HE

Year
2021
Year Level
master, master
Course Code
GW4592M

Master Thesis HEPL

Level
master
Year
2021
Year Level
master
Course Code
GW4555M

Academic Development & Skills

Level
bachelor 2
Year
2021
Year Level
bachelor 2
Course Code
GW205AVV

Integration project

Level
bachelor 2
Year
2021
Year Level
bachelor 2
Course Code
GW205I

Module Knowledge

Level
bachelor 2
Year
2021
Year Level
bachelor 2
Course Code
GW205K

Health Economics

Year
2021
Course Code
MEP-ESP25

Vergelijk @count opleiding

  • @title

    • Tijdsduur: @duration
Vergelijk opleidingen